Development of Innovative, Effective, and Safe New Cancer Drugs

Pursuit of Increased Patient Survival and Improved Quality of Life

About Oblato

Oblato, Inc. is a pharmaceutical company focused on the development and commercialization of novel cancer therapeutics. Oblato has been developing OKN-007 for the treatment of brain cancers.

Our Science

OKN-007, nitrone derivative, is a free radical scavenger that eliminates reactive oxygen species and reduces necrosis, hypoxia, inflammation, and angiogenesis.


OKN-007 is a new and novel medicine for treatment of brain cancers, GBM and DIPG.

Clinical Development

Clinical trials are ongoing to investigate the safety and efficacy using OKN-007 for patients with both newly diagnosed and recurrent GBM.


GBM is a fast-growing glioma that develops from star-shaped glial cells.
DIPG is a type of brain tumor found in an area of the brainstem know as the pons.

News & Media

Contact Us